Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA575952
Title Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex.
Publication Date Sep 2012
Media Count 7p
Personal Author M. K. Koenig
Abstract Tuberous Sclerosis Complex (TSC) is a genetic disorder resulting from mutations in either the TSC1 or TSC2 genes. TSC is characterized by abnormal skin pigmentation and tumor formation in multiple organ systems. The TSC1 and TSC2 gene products are involved in cell signaling; in particular they are involved in the mammalian target of rapamycin (mTOR) signaling pathway. In TSC, the epidermal basal cells contain a mutant copy of either the TSC1 or TSC2 gene. A loss of heterozygosity results in constitutive activation of mTOR leading to production of epidermal cells at a faster rate than the ability to slough the dead cells. This overproduction of skin cells, in conjunction with angiogenesis, results in the formation of visible facial angiofibromas over time. The lesions appear as red or pink papules distributed over the central face, especially on the nasolabial folds, cheeks, and chin. Lesions appear in early childhood and are present in up to 80% of TSC patients. Facial angiofibromas create considerable cosmetic morbidity for patients with TSC and currently there is no effective method for preventing or permanently removing them. Rapamycin is a naturally occurring antifungal macrolide that binds with high specificity to mTOR resulting in inhibition of mTOR activity and ultimately in downregulation of cell growth. Systemically administered rapamycin has an unfavorable side effect profile, limiting its potential use. Commonly reported side effects include oral ulcers, hyperlipidemia, thrombocytopenia, acneiform rash, immunosuppression, and impaired wound healing. Rapamycin has a molecular weight of 914.2 grams, allowing for its absorption through the superficial layers of the epidermis.
Keywords Abnormalities
Angiofibroma
Cells(Biology)
Epidermis
Face(Anatomy)
Genetics
Healing
Inhibition
Mammals
Molecular weight
Mutations
Neoplasms
Oral intake
Order disorder transformations
Organs(Anatomy)
Patients
Pigments
Rapamycin
Sebaceous adenoma
Signals
Skin diseases
Skin(Anatomy)
Tuberous sclerosis complex
Ulcers
Wounds and injuries


 
Source Agency Non Paid ADAS
NTIS Subject Category 57F - Cytology, Genetics, & Molecular Biology
57E - Clinical Medicine
Corporate Author Texas Univ. Medical School at Houston.
Document Type Technical report
Title Note Annual rept. 1 Sep 2011-31 Aug 2012.
NTIS Issue Number 1319
Contract Number W81XWH-11-1-0240

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader